Icagen, Inc., Durham, NC 27703, USA.
Expert Opin Ther Pat. 2010 Nov;20(11):1471-503. doi: 10.1517/13543776.2010.513384. Epub 2010 Aug 20.
The human genome encodes at least 40 distinct voltage-gated potassium channel subtypes, which vary in regional expression, pharmacological and biophysical properties. Voltage-dependent potassium (Kv) channels help orchestrate many of the physiological and pathophysiological processes that promote and sometimes hinder the healthy functioning of our bodies.
This review summarizes patent and scientific literature reports from the past decade highlighting the opportunities that Kv channels offer for the development of new therapeutic interventions for a wide variety of disorders.
The reader will gain an insight from an analysis of the associations of different Kv family members with disease processes, summary and evaluation of the development of therapeutically relevant pharmacological modulators of these channels, particularly focusing on proprietary agents being developed.
Development of new drugs that target Kv channels continue to be of great interest but is proving to be challenging. Nevertheless, opportunities for Kv channel modulators to have an impact on a wide range of disorders in the future remain an exciting prospect.
人类基因组至少编码 40 种不同的电压门控钾通道亚型,它们在区域表达、药理学和生物物理学特性上有所不同。电压依赖性钾 (Kv) 通道有助于协调许多促进和有时阻碍我们身体正常功能的生理和病理生理过程。
本综述总结了过去十年中专利和科学文献报告,强调了 Kv 通道为广泛的各种疾病开发新治疗干预措施提供的机会。
读者将从不同 Kv 家族成员与疾病过程的关联分析中获得深入了解,总结和评估这些通道的治疗相关药理学调节剂的开发,特别关注正在开发的专有制剂。
开发针对 Kv 通道的新药仍然非常有意义,但事实证明具有挑战性。尽管如此,未来 Kv 通道调节剂在广泛的疾病中产生影响的机会仍然是一个令人兴奋的前景。